Literature DB >> 23769799

Aflibercept for the treatment of refractory polypoidal choroidal vasculopathy.

Yoshihiro Yonekawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23769799     DOI： 10.1016/j.jcjo.2012.12.015

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  4 in total

Review 1.  Clinical characteristics and current treatment of age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Ivana K Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-03       Impact factor: 6.915

2.  High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population.

Authors:  D M Marcus; H Singh; C M Fechter; D P Chamberlain
Journal:  Eye (Lond)       Date:  2015-09-04       Impact factor: 3.775

3.  One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy.

Authors:  Marta Medina-Baena; María Jesús Huertos-Carrillo; Laura Rodríguez; Juan Ignacio García-Pulido; Carlos Cornejo-Castillo; José María Calandria-Amiguetti
Journal:  Case Rep Ophthalmol       Date:  2018-03-02

Review 4.  Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.

Authors:  Alfredo García-Layana; Marta S Figueroa; Javier Araiz; José M Ruiz-Moreno; Francisco Gómez-Ulla; Luis Arias-Barquet; Nicholas Reiter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.